210 related articles for article (PubMed ID: 32347094)
1. Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
Han G; Liu N; Li C; Tu J; Li Z; Sheng C
J Med Chem; 2020 May; 63(10):5341-5359. PubMed ID: 32347094
[TBL] [Abstract][Full Text] [Related]
2. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
Zhu T; Chen X; Li C; Tu J; Liu N; Xu D; Sheng C
Eur J Med Chem; 2021 Oct; 221():113524. PubMed ID: 33992927
[TBL] [Abstract][Full Text] [Related]
3. Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
Li Z; Tu J; Han G; Liu N; Sheng C
J Med Chem; 2021 Jan; 64(2):1116-1126. PubMed ID: 33356256
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
Li C; Tu J; Han G; Liu N; Sheng C
Eur J Med Chem; 2022 Jan; 227():113961. PubMed ID: 34742014
[TBL] [Abstract][Full Text] [Related]
5. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
Keniya MV; Ruma YN; Tyndall JDA; Monk BC
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
[TBL] [Abstract][Full Text] [Related]
6. Structural and Functional Elucidation of Yeast Lanosterol 14α-Demethylase in Complex with Agrochemical Antifungals.
Tyndall JD; Sabherwal M; Sagatova AA; Keniya MV; Negroni J; Wilson RK; Woods MA; Tietjen K; Monk BC
PLoS One; 2016; 11(12):e0167485. PubMed ID: 27907120
[TBL] [Abstract][Full Text] [Related]
7. Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design.
Monk BC; Sagatova AA; Hosseini P; Ruma YN; Wilson RK; Keniya MV
Biochim Biophys Acta Proteins Proteom; 2020 Mar; 1868(3):140206. PubMed ID: 30851431
[TBL] [Abstract][Full Text] [Related]
8. Antifungal screening and in silico mechanistic studies of an in-house azole library.
Sari S; Kart D; Sabuncuoğlu S; Doğan İS; Özdemir Z; Bozbey İ; Gencel M; Eşsiz Ş; Reynisson J; Karakurt A; Saraç S; Dalkara S
Chem Biol Drug Des; 2019 Sep; 94(5):1944-1955. PubMed ID: 31260179
[TBL] [Abstract][Full Text] [Related]
9. The amino acid substitution N136Y in Candida albicans sterol 14alpha-demethylase is involved in fluconazole resistance.
Alvarez-Rueda N; Fleury A; Logé C; Pagniez F; Robert E; Morio F; Le Pape P
Med Mycol; 2016 Oct; 54(7):764-775. PubMed ID: 27143634
[TBL] [Abstract][Full Text] [Related]
10. Molecular Docking Evaluation of Imidazole Analogues as Potent Candida albicans 14α-Demethylase Inhibitors.
Rani N; Kumar P; Singh R; Sharma A
Curr Comput Aided Drug Des; 2015; 11(1):8-20. PubMed ID: 26081558
[TBL] [Abstract][Full Text] [Related]
11. Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens.
Becher R; Wirsel SG
Appl Microbiol Biotechnol; 2012 Aug; 95(4):825-40. PubMed ID: 22684327
[TBL] [Abstract][Full Text] [Related]
12. Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosa.
Warrilow AG; Price CL; Parker JE; Rolley NJ; Smyrniotis CJ; Hughes DD; Thoss V; Nes WD; Kelly DE; Holman TR; Kelly SL
Sci Rep; 2016 Jun; 6():27690. PubMed ID: 27291783
[TBL] [Abstract][Full Text] [Related]
13. In silico and in vitro screening to identify structurally diverse non-azole CYP51 inhibitors as potent antifungal agent.
Singh A; Paliwal SK; Sharma M; Mittal A; Sharma S; Sharma JP
J Mol Graph Model; 2016 Jan; 63():1-7. PubMed ID: 26579619
[TBL] [Abstract][Full Text] [Related]
14. Structural analyses of
Hargrove TY; Friggeri L; Wawrzak Z; Qi A; Hoekstra WJ; Schotzinger RJ; York JD; Guengerich FP; Lepesheva GI
J Biol Chem; 2017 Apr; 292(16):6728-6743. PubMed ID: 28258218
[TBL] [Abstract][Full Text] [Related]
15. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI
J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in antifungal drug development targeting lanosterol 14α-demethylase (CYP51): A comprehensive review with structural and molecular insights.
Singh A; Singh K; Sharma A; Kaur K; Chadha R; Bedi PMS
Chem Biol Drug Des; 2023 Sep; 102(3):606-639. PubMed ID: 37220949
[TBL] [Abstract][Full Text] [Related]
17. Shape and pharmacophore-based virtual screening to identify potential cytochrome P450 sterol 14α-demethylase inhibitors.
Reddy KK; Singh SK; Tripathi SK; Selvaraj C; Suryanarayanan V
J Recept Signal Transduct Res; 2013 Aug; 33(4):234-43. PubMed ID: 23638723
[TBL] [Abstract][Full Text] [Related]
18. Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
Yates CM; Garvey EP; Shaver SR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2017 Aug; 27(15):3243-3248. PubMed ID: 28651982
[TBL] [Abstract][Full Text] [Related]
19. An Erg11 lanosterol 14-α-demethylase-Arv1 complex is required for Candida albicans virulence.
Villasmil ML; Barbosa AD; Cunningham JL; Siniossoglou S; Nickels JT
PLoS One; 2020; 15(7):e0235746. PubMed ID: 32678853
[TBL] [Abstract][Full Text] [Related]
20. Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.
Sagatova AA; Keniya MV; Wilson RK; Monk BC; Tyndall JD
Antimicrob Agents Chemother; 2015 Aug; 59(8):4982-9. PubMed ID: 26055382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
